Navigation Links
The Forsyth Institute receives Grand Challenges tuberculosis biomarkers grant
Date:2/9/2012

CAMBRIDGE, Mass., − The Forsyth Institute announced today that it will receive a tuberculosis (TB) biomarkers grant through the Bill & Melinda Gates Foundation's Grand Challenges in Global Health program, an initiative which seeks to overcome persistent bottlenecks in creating new tools that can radically improve health in the developing world. Antonio Campos-Neto, MD, PhD, Head of the Global Infectious Disease Research Center at Forsyth will pursue an innovative research project to identify and validate TB biomarkers, titled "Validation of the diagnostic utility of Mtb protein biomarkers found in urine of TB patients".

The Grand Challenges TB biomarkers program provides funding for groundbreaking research into TB biomarkers for the development of a low-cost, simple to use tool that can quickly and accurately diagnose TB in developing countries.

"There is an urgent need to break through barriers in biomarker research in order to develop a highly-sensitive point-of-care diagnostic to improve identification of active TB cases," said Chris Wilson, Director of Global Health Discovery at the Bill & Melinda Gates Foundation. "We hope these innovative ideas lead to effective and affordable TB diagnostics that can make an impact on one of the world's deadliest infectious diseases."

Dr. Campos-Neto's project is one of ten Grand Challenges TB biomarkers grants announced today.

Dr. Campos-Neto is working on the development of an antigen detection assay for the diagnosis of TB based on a single urine sample. His research focuses on the diagnosis of active TB through a technique that could be similar to a simple home-pregnancy test. Current diagnostic tests for TB have several shortcomings. Traditional TB tests focus on the direct identification of the infectious agent in the sputum of patients with active disease, which typically occurs when the patient presents with a persistent cough. These tests have limited sensitivity and are time-consuming, in some cases requiring up to six weeks to collect and examine samples. The test that Dr. Campos-Neto hopes to develop will overcome the challenges of existing tests and will accurately diagnose active TB.

The immediate goal of the project is to validate seven proteins of Mycobacterium tuberculosis (the agent of TB) as biomarkers of active disease. This work will be done in collaboration with Dr. David Duffy, Quanterix Corp, Cambridge, Mass., and Dr. Nira Pollock, Beth Israel Deaconess Medical Center, Boston, Mass.


'/>"/>

Contact: Jennifer Kelly
jkelly@forsyth.org
617-892-8602
Forsyth Institute
Source:Eurekalert

Related biology news :

1. Forsyth scientists trigger cancer-like response from embryonic stem cells
2. Forsyth scientist receives major grant to support rapid, accurate, affordable test for tuberculosis
3. Forsyth scientists suggest linkages between obesity and oral bacterial infection
4. Forsyth receives highly competitive challenge grants
5. Forsyth scientists support the Human Microbiome Project
6. Forsyth team gains new insight on childhood dental disease
7. Wistar Institute researcher receives New Innovator award from NIH
8. Swiss Institute of Bioinformatics celebrates 10th birthday by presenting major gifts to human health
9. Broad Institute awarded major grant to bolster epigenomics research
10. Salk researcher Terry Sejnowski elected to Institute of Medicine
11. EPA teams with National Geographic Society and World Resources Institute to map ecosystem services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/14/2017)... , Feb. 14, 2017  Wake Forest Baptist ... as its new chief executive officer (CEO). Freischlag joins ... John D. McConnell , M.D., who last year ... at the Medical Center, after leading it since 2008. ... full scope of Wake Forest Baptist,s academic health system, ...
(Date:2/10/2017)... Research and Markets has announced ... - Scientific and Commercial Aspects" to their offering. ... Biomarkers ... with therapy for selection of treatment as well for monitoring ... of disease in modern medicine. Biochip/microarray technologies and next generation ...
(Date:2/8/2017)... BEDFORD, Mass., Feb. 7, 2017  Aware, Inc. (NASDAQ: ... services, today reported financial results for its quarter and year ... fourth quarter of 2016 was $3.9 million compared to $6.9 ... the fourth quarter of 2016 was $0.6 million compared to ... in the fourth quarter of 2016 was $0.5 million, or ...
Breaking Biology News(10 mins):
(Date:3/1/2017)... 1, 2017  Cryoport (NASDAQ: CYRX, CYRXW) ("Cryoport" or ... to the life sciences industry, today announced the launch ... reproductive health market. CryoStork SM Next Flight Out ... for reproductive health patients, providing express transportation across ... for reproductive health commodities such as sperm, eggs, embryos ...
(Date:3/1/2017)... SHANGHAI , March 1, 2017 ... Cork based Biotechnology Company and HD ... discovery Contract Research Organization (CRO), announced today that ... and provide new assay technologies for preclinical drug ... access to Luxcel,s state-of-the-art assays and technologies for ...
(Date:3/1/2017)... WA (PRWEB) , ... March 01, 2017 , ... ... research into the physiology of aging into clinical applications, announces the formation of ... proprietary oral-transmucosal dosage form of resveratrol, the drug which has been discussed in ...
(Date:2/28/2017)... ... , ... Surface Plasmon Resonance (SPR) is a widely-used, label-free technique to characterize ... changes in the dielectric properties of the medium close to a metal surface. ... to 300 nm above the metal surface (Au) and thus by the material absorbed ...
Breaking Biology Technology: